• 1
    Jager A, Kuchroo VK. Effector and regulatory T cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 2010; 72:17384.
  • 2
    Dumitriu IE, Araguas ET, Baboonian C, Kaski JC. CD4+CD28null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 2009; 81:1119.
  • 3
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:88399.
  • 4
    Zamarron BF, Chen WJ. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7:6518.
  • 5
    Goverman J, Brabb T, Paez A, Harrington C, von Dassow P. Initiation and regulation of CNS autoimmunity. Crit Rev Immunol 1997; 17:46980.
  • 6
    Burns J, Rosenzwerg A, Zwerman B, Lisak RP. Isolation of myelin basic protein-reactive T cell lines from normal human blood. Cell Immunol 1983; 81:43540.
  • 7
    Homann D, von Herrath M. Regulatory T cells and type 1 diabetes. Clin Immunol 2004; 112:2029.
  • 8
    Hoyne GF. Mechanisms that regulate peripheral immune responses to control organ-specific autoimmunity. Clin Dev Immunol 2011; 2011:294968 Epub 2011 28 April.
  • 9
    Bubanovic I. Auto-immunity as evolutionary by product of adoptive immunity and source of anti-tumor immunity failure. Int J Cancer Res 2005; 1:816.
  • 10
    Brooks-Worrell B, Palmer JPP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57:15861.
  • 11
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:118397.
  • 12
    McCance DR, Hanson RL, Pettitt DF, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus: do we need new criteria? Diabetologia 1997; 40:24755.
  • 13
    Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J Exp Med 1987; 166:82332.
  • 14
    Miller BJ, Appel MC, O'Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:528.
  • 15
    Lampeter EF, Homberg M, Quabeck K et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341:12434.
  • 16
    Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009; 115:2407.
  • 17
    Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes. Diabetes Care 2008; 31:S1614.
  • 18
    Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009; 24:32531.
  • 19
    Boni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008; 10:S20S204.
  • 20
    Kintscher U, Hartge M, Hess K et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28:130410.
  • 21
    Nishimura S, Manabe I, Nagasaki M et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15:91420.
  • 22
    Winer S, Chan Y, Paltser G et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15:9219.
  • 23
    Wu H, Ghosh S, Perrard XD et al. T-cell accumulation and regulation on activation, normal T cell expressed and secreted up-regulation in adipose tissue in obesity. Circulation 2007; 115:102938.
  • 24
    Feuerer M, Herrero L, Cipolletta D et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameter. Nat Med 2009; 15:93040.
  • 25
    Deiuliis J, Shah Z, Shah N et al. Visceral adipose inflammation in obesity is associated with critical alterations in T regulatory cell numbers. PLoS ONE 2011; 6:e16376. doi:10.1371/journal.pone.0016376.
  • 26
    Ilan Y, Maron R, Tukpah A-M et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci 2010; 107:976570.
  • 27
    Meijer K, de Vries M, Al-Lahham S et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS ONE 2011; 6:e17154. doi: 10.1371/journal.pone.0017154.
  • 28
    Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 2003; 52:81217.
  • 29
    Herder C, Brunner EJ, Rathmann W et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32:4213.
  • 30
    Pradhan DA, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:32734.
  • 31
    Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98107.
  • 32
    Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:151726.
  • 33
    Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152:34657.
  • 34
    Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1β-induced insulin resistance in adipocytes through down-relation of insulin receptor substrate-1 expression. Endocrinology 2007; 148:24151.
  • 35
    Weigert C, Hennige AM, Lehmann R et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 2006; 281:70607.
  • 36
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259:8791.
  • 37
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389:61014.
  • 38
    Lee MS. Role of innate immunity in diabetes and metabolism: recent progress in the study of inflammasomes. Immune Netw 2011; 11:959.
  • 39
    Pickup JC. Inflammation and activation innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27:81323.
  • 40
    Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, an the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167:16705.
  • 41
    Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gasteroenterol Hepatol 2006; 4:4828.
  • 42
    Deckert M, Sanchez-Ruiz M, Brunn A, Schluter D. Role of CD8 T-cell-mediated autoimmune diseases of the central nervous system. Crit Rev Immunol 2010; 30:31126.
  • 43
    Mars LT, Saikali P, Liblau RS, Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta 2011; 1812:15161.
  • 44
    Zierden M, Kuhnen E, Odenthal M, Dienes HP. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gasteroenterology 2010; 139:97586.
  • 45
    Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Adaptive immunity in autoimmune hepatitis. Dig Dis 2010; 28:639.
  • 46
    Faustman DL, Davis M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J Mol Med 2009; 87:11738.
  • 47
    Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:82152.
  • 48
    Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87113.
  • 49
    Winer S, Paltser G, Chan Y et al. Obesity predisposes to TH17 bias. Eur J Immunol 2009; 39:262935.
  • 50
    Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Auto-immune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:16975.
  • 51
    Cnop M, Welsh N, Jonas J-C, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes. Diabetes 2005; 545 (Suppl. 2):S97S107.
  • 52
    Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003; 66:143340.
  • 53
    DeFronzo RA, Tipathy D, Schwenke DC et al. for the ACT NOW study. Pioglitazone for Diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:110415.
  • 54
    Seyfert-Margolis V, Gisler TD, Asare AL et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006; 55:258894.
  • 55
    Herold KC, Brooks-Worrell B, Palmer JPP et al. The type 1 diabetes TrailNet research group: validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58:258895.
  • 56
    Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JPP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients: respond to multiple islet cell proteins. J Immunol 1996; 157:566874.
  • 57
    Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001; 166:526570.
  • 58
    Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JPP. Cellular immune response to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48:9838.
  • 59
    Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JPP. Identification of autoantibody-negative autoimmune type 2 diabetes patients. Diabetes Care 2011; 34:16873.
  • 60
    Goel A, Chiu H, Felton J, Palmer JPP, Brooks-Worrell B. T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56:211015.
  • 61
    Foryst-Ludwig A, Hertge M, Clemenz M et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol 2010; 9:6472.
  • 62
    Wang J, Miao D, Babu S et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007; 92:8892.
  • 63
    Nagata M, Moriyama H, Kotani R et al. Immunological aspects of ‘fulminant type 1’ diabetes. Diabetes Res Clin Pract 2007; 77:15.
  • 64
    Verge CF, Gianani R, Kawasake I et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes. J Autoimmun 1996; 9:37083.
  • 65
    Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998; 161:69639.
  • 66
    Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA 512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998; 47:73342.
  • 67
    Greenbaum CJ, Brooks-Worrell BM, Palmer JPP, Lernmark A. Autoimmunity and prediction of insulin dependent diabetes mellitus. In: Marshal SM, Home PD, eds. The diabetes annual/8. Amsterdam: Elsevier, 1994:219.
  • 68
    Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JPP. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50:100813.
  • 69
    Mayer A, Fabien N, Gutowski MC et al. Contrasting cellular and humoral autoimmunity associated with latent autoimmune diabetes in adults. Eur J Endocrinol 2007; 157:5361.
  • 70
    Zavala AV, Fabiano de Bruno LE, Cardoso AI et al. Cellular and humoral autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia 1992; 35:115964.
  • 71
    Hosszufalusi N, Yatay A, Rajczy K et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003; 26:4527.
  • 72
    Murao S, Kondo S, Ohashi J et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA) – a 5 year follow-up of the Ehime study. Diabetes Res Clin Pract 2008; 38:11421.
  • 73
    Wenzlau JM, Moua O, Sarkar SA et al. SIC30A8 is a major target of humoral autoimmunity in Type 1 diabetes and a predictive marker in prediabetes. Immunology of diabetes V. Ann NY Acad Sci 2008; 1150:2569.
  • 74
    Seissler J, DeSonnaville JJJ, Morgenthaler NG et al. Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41:8917.
  • 75
    Palmer JPP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54:S6267.
  • 76
    Abraham A, Donaghue KC, Chan AK, Benitez-Aguirre P, Lloyd M, Craig ME. Adiposity at diagnosis of childhood type 1 diabetes – have we reached a plateau? Diabetes 2011; 60:A4344.
  • 77
    Klingensmith GJ, Kaminski BM, Diabetes P. Consortium: obesity and DKA are common in youth at T1D onset: findings of the pediatric diabetes consortium (PDC). Diabetes 2011; 60:A340.
  • 78
    Libman I, Hughan K, Giwa A, Lee S, Beker D, Arslanian S. Are overweight children with type 1 diabetes mellitus (T1DM) at increased risk of cardiovascular disease (CVD)? Diabetes 2011; 60:A333.
  • 79
    Faulkner MS, Michaliszyn SF, Going S, Wheeler MD. Body mass index and waist circumference are associated with C-reactive protein and heart rate variability in adolescents with Type 1 diabetes. Diabetes 2011; 60:A341.